Tranexamic Acid Reduces Blood Loss after Off-Pump Coronary Surgery

Guyan Wang,Gaoqiang Xie,Tingting Jiang,Yuefu Wang,Weipeng Wang,Hongwen Ji,Mingzheng Liu,Lei Chen,Lihuan Li

DOI: https://doi.org/10.1097/01.sa.0000426520.40443.45

2013-01-01

Survey of Anesthesiology

Abstract:Wang, Guyan; Xie, Gaoqiang; Jiang, Tingting; Wang, Yuefu; Wang, Weipeng; Ji, Hongwen; Liu, Mingzheng; Chen, Lei; Li, Lihuan Author Information

What problem does this paper attempt to address?

Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study.

Guyan Wang,Gaoqiang Xie,Tingting Jiang,Yuefu Wang,Weipeng Wang,Hongwen Ji,Mingzheng Liu,Lei Chen,Lihuan Li

DOI: https://doi.org/10.1213/ANE.0b013e3182264a11

2012-01-01

Abstract:BACKGROUND: Bleeding and the need for allogeneic transfusions are still problems after off-pump coronary artery bypass grafting (OPCAB) surgery. We therefore evaluated the effects of an antifibrinolytic, tranexamic acid, on postoperative bleeding and transfusion requirements in patients undergoing OPCAB surgery. METHODS: Two hundred thirty-one consecutive patients scheduled for elective OPCAB were enrolled in the study. Using a double-blind method, the patients were randomly assigned to receive either tranexamic acid (bolus 1 g before surgical incision followed by an infusion of 400 mg/h during surgery; n = 116) or a placebo (infusion equivalent volume of saline solution; n = 115). The primary outcome was 24-hour postoperative chest tube drainage. Allogeneic transfusion, mortality, major morbidities, and resource utilization were also recorded. RESULTS: In comparison with the placebo group, the patients receiving tranexamic acid had a significant reduction in chest tube drainage at 6 hours (270 118 mL vs 416 179 mL, P < 0.001) and 24 hours (654 +/- 224 mL vs 891 +/- 295 mL, P<0.001). There was also a significant reduction in allogeneic red blood cell transfusions (47% vs 31.9%, P = 0.019) and fresh frozen plasma (29.6% vs 17.2%, P = 0.027) transfusions. There were no differences in mortality, morbidity, and resource utilization between the 2 groups. CONCLUSIONS: Tranexamic acid reduces postoperative chest tube drainage and the requirement for allogeneic transfusion in off-pump coronary surgery. (Anesth Analg 2012;115:239-43)
Tranexamic acid reduces postoperative bleeding in coronary artery bypass graft

REN Mingming,HAN Zhen,LI Jinglai,CHENG Ying,WU Yongqian

DOI: https://doi.org/10.3969/j.issn.1674-4721.2010.19.035

2010-01-01

Abstract:Objective:To evaluate the treatment effect of tranexamic acid reduces postoperative blood loss in coronary artery bypass surgery. Methods:60 patients undergoing coronary artery bypass graft(CABG) from June 2006 to October 2009 in department of cardiac surgical were randomly selected and enrolled into the study,and divided into tranexamic acid(TA) group(31 patients) and placebo group(29 patients) ,the TA group received an intravenous TA before the skin incision and followed by a continuous infusion,the placebo group received an identical syringe of normal saline solution. The effect of TA reduced total blood loss in 24 h and the blood transfusion were observed. Also observed the change of Ddimer level. Results:24 hours postoperative blood loss was significantly less in the tranexamic acid group(450 ±205) ml than that of the placebo group(863±343) ml,and the intraoperative blood transfusion in TA group was significantly less than that of placebo group. There was significant increase in plasma D-dimer levels after CABG only in patients of the placebo group,whereas no significant changes were observed in the group treated with tranexamic acid. Conclusion:Compare to the placebo group,trannexamic acid may play a role in anti-fibrinolytic and appears to be effective in reducing the postoperative blood loss.
Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss Control in Patients Undergoing Cesarean Delivery: a Systematic Review and Meta-Analysis

Fan Yang,Han Wang,Mengdie Shen

DOI: https://doi.org/10.1186/s12884-023-05753-9

2023-01-01

BMC Pregnancy and Childbirth

Abstract:Postpartum hemorrhage (PPH) is one of the important risk factors leading to maternal mortality and intervention is essential. Oxytocin therapy is widely used clinically, but the effect is unsatisfactory. The efficacy of tranexamic acid (TXA) in hemostasis is notable, whereas its use in preventing PPH warrants exploration.To evaluate the effect of prophylactic administration of TXA on perioperative blood loss in women undergoing cesarean section by systematic review and meta-analysis of published studies.Bibliographic databases were screened from their inception to December 2022 to retrieve relevant studies. Study outcomes including blood loss during cesarean section, 2-h postpartum blood loss, total blood loss (during cesarean section and 2-h postpartum), and 6-h postpartum, as well as hemoglobin changes were extracted and compared.A total of 21 studies, nine randomized clinical trials and 12 cohort studies, involving 1896 patients given TXA prophylactically and 1909 patients given placebo or no treatment, were analyzed. Compared with the control group, the preoperative prophylactic intravenous administration of TXA significantly reduced the intraoperative (RCT: P < 0.00001, cohort studies: P < 0.00001), 2-h postpartum (RCT: P = 0.02, cohort studies: P < 0.00001) and total blood loss (RCT: P < 0.00001, cohort studies: P = 0.0002), and reduced the decline in hemoglobin (RCT: P < 0.00001, cohort studies: P = 0.0001), but did not significantly affect blood loss at 6-h postpartum (P = 0.05).Prophylactic intravenous TXA before cesarean section is helpful in preventing perioperative bleeding in women.http://www.crd.york.ac.uk/PROSPERO , identifier: CRD 42022363450.
Tranexamic acid for upper gastrointestinal bleeding

Lise Lotte Gluud,Sarah Louise Klingenberg,Ebbe Langholz

DOI: https://doi.org/10.1002/14651858.CD006640.pub2

2012-01-18

Abstract:Background: Tranexamic acid reduces haemorrhage through its antifibrinolytic effects. In a previous version of the present review, we found that tranexamic acid may reduce mortality. The present review includes updated searches of randomised trials on tranexamic acid versus placebo, cimetidine or lansoprazole. Objectives: To assess the effects of tranexamic acid for upper gastrointestinal bleeding. Search methods: Electronic searches (The Cochrane Library, MEDLINE, EMBASE, Science Citation Index) and manual searches were combined. The last search update was in October 2011. Selection criteria: Trials in which patients with upper gastrointestinal bleeding were randomised to receive either tranexamic acid or placebo, or any anti-ulcer drug, were included. Data collection and analysis: Two authors independently extracted data. All-cause mortality was the primary outcome measure. Random-effects model meta-analyses were performed and results presented as relative risks (RR) with 95% confidence intervals (CI). Subgroup, sensitivity, regression and sequential analyses were performed to analyse sources of intertrial heterogeneity and the robustness of the overall result. Main results: Seven double blind randomised trials on tranexamic acid versus placebo, cimetidine, or lanzoprazole were included. One trial offered endoscopic treatment to all patients that were randomised. Random-effects model meta-analysis found that tranexmic acid reduced mortality compared with placebo (41 of 829 versus 68 of 825 patients; RR: 0.61, 95% CI 0.42 to 0.89). The beneficial effect was not confirmed in subgroup analysis stratified for the quality of bias control, in worst case scenario analyses (in which 21% of the randomised patients were excluded), or in sequential analyses. No significant differences were found between tranexamic acid and placebo on bleeding, surgery, or transfusion requirements. No clear effects of tranexamic acid were identified in trials using endoscopic therapy or in the trials comparing tranexamic acid with cimetidine or lansoprazole. In the tranexamic acid group, five cases of serious thromboembolic events occurred (myocardial infarction, pulmonary embolism, and cerebral infarction). Overall, the number of patients with any thrombotic event was not significantly increased in the tranexamic acid group (RR 1.87, 95% CI 0.60 to 5.85). Authors' conclusions: Considering the internal and external validity of the evidence, tranexamic acid cannot be recommended for routine use. Additional trials in which tranexamic acid is used in combination with the currently recommended interventions are required.
Effectiveness And Safety Of Tranexamic Acid In Reducing Blood Loss In Total Knee Arthroplasty: A Meta-Analysis

Zhi-Gao Yang,Wei-Ping Chen,Li-Dong Wu

DOI: https://doi.org/10.2106/JBJS.K.00873

2012-01-01

Abstract:Background: Total knee arthroplasty is associated with substantial blood loss and the risks of transfusion. Conflicting reports have been published regarding the effectiveness and safety of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty. We performed a meta-analysis to investigate the effectiveness and safety of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty.Methods: A meta-analysis was performed to assess the effectiveness and safety of using tranexamic acid in total knee arthroplasty. Randomized controlled trials that had been published before May 2011 were retrieved, and fifteen studies met the inclusion criteria. The weighted mean difference in blood loss, number of transfusions per patient, prothrombin time, and postoperative activated partial thromboplastin time and the summary odds ratio of transfusion, deep-vein thrombosis, and pulmonary embolism were calculated in the group of patients who received tranexamic acid and the group of patients who received a placebo.Results: The amount of blood loss and the number of blood transfusions per patient were significantly less and the proportion of patients who required a blood transfusion was smaller in the tranexamic acid group compared with the placebo group. No significant difference in prothrombin time, activated partial thromboplastin time, deep-vein thrombosis, and pulmonary embolism was detected between the tranexamic acid group and the placebo group.Conclusions: The meta-analysis shows that the use of tranexamic acid for patients undergoing total knee arthroplasty is effective and safe for the reduction of blood loss.
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials

Xin-die Zhou,Li-jiang Tao,Jin Li,Li-dong Wu

DOI: https://doi.org/10.1007/s00402-013-1761-2

IF: 2.928

2013-01-01

Archives of Orthopaedic and Trauma Surgery

Abstract:Background Studies have shown that tranexamic acid reduces blood loss and transfusion need in patients undergoing total hip arthroplasty. However, no to date, no study has been large enough to determine definitively whether the drug is safe and effective. We examined whether intravenous tranexamic acid, when compared with placebo, was safe and effective in total hip arthroplasty. Methods The literature search was conducted using the PubMed, Cochrane Library, MEDLINE, EMBASE, and China National Knowledge Infrastructure (CNKI) databases. Data were evaluated using the generic evaluation tool designed by the Cochrane Bone, Joint and Muscle Trauma Group. Ultimately, 19 randomized controlled trials involving 1,030 patients were included. Results The use of tranexamic acid significantly reduced total blood loss by a mean of 305.27 mL [95 % confidence interval (CI) −397.66 to −212.89, p < 0.001], intraoperative blood loss by a mean of 86.33 mL(95 % CI −152.29 to −20.37, p = 0.01), postoperative blood loss by a mean of 176.79 mL (95 % CI −236.78 to −116.39, p < 0.001), and “hidden” blood loss by a mean of 152.70 mL (95 % CI −187.98 to −117.42, p < 0.001), resulting in a meaningful reduction in the proportion of patients requiring blood transfusion (odds ratio 0.28, 95 % CI 0.19 to 0.42, p < 0.001). There was no significant difference in occurrence of deep vein thrombosis, pulmonary embolism, or other complications among the study groups, or cost or hospitalization duration. Conclusions The data from this meta-analysis indicate that intravenous tranexamic acid may reduce blood loss and transfusion need in patients undergoing total hip arthroplasty without increasing the risk of complications. However, high-quality randomized controlled trials are required to validate the results.
Systemic Tranexamic Acid for Reduced Postoperative Blood Loss and Less Bleeding Complications in Fleur-de-lis Abdominoplasty and Apronectomy

Carolin Wachtel,Jens Rothenberger,Ines Ana Ederer,Jochen Souquet,Ulrich Rieger

DOI: https://doi.org/10.1007/s00266-024-03992-5

IF: 2.708

2024-03-31

Aesthetic Plastic Surgery

Abstract:Strategies minimizing surgical bleeding, including the antifibrinolytic agent tranexamic acid, play a crucial role in clinical practice to optimize overall surgical outcomes. Despite its proven efficacy in various clinical fields, there is a limited understanding regarding the use of tranexamic acid in plastic and aesthetic procedures. This study is the first investigating the effects of systemically administered tranexamic acid on postoperative blood loss and bleeding complications in fleur-de-lis abdominoplasties and apronectomies.

surgery
Effects of tranexamic acid in total knee arthroplasty by intra-articular injection on reducing blood loss：a prospective randomized controlled study

Lingtian Min,Wenjie Weng,Yong Qiu,Weijun Wang,Tao Yuan,Mingda Wu,Jiayi Li,Fei Liu

DOI: https://doi.org/10.3877/cma.j.issn.1674-134X.2014.04.015

2014-01-01

Abstract:Objective To assess the efficacy and safety of tranexamic acid in reducing the blood loss during the primary total knee arthroplasty ( TKA ) by intra-articular injection . Methods A prospective randomized controlled study was carried out , including 60 patients who underwent the primary TKA by the same surgeon team on a standardized technique .Each group instantly accepted 50 ml normal saline intra-articular injection postoperatively with 3.0 g tranexamic acid dissolved in or not .Each patient had negative pressure drainage after the drainage-tube clamped for one hour and received the blood routine examination and the blood coagulation indicator test; their daily drainage in the first three days was recorded postoperatively .The vein angiography of the lower limb was carried out within 3 -5 days to observe the incidence of thrombosis .Results The postoperative drainge and the total blood loss in the tranexamic acid group were significantly less than the control group .The number of the patients accepted transfusion in the tranexamic group was significant smaller than that in the control group .There was no significant difference between the two groups in terms of postoperative coagulation function , thromboembolic events or other adverse events .Conclusion Tranexamic acid is effective in reducing the postoperative blood loss by intra-articular injection in primary TKA without increasing the incidence of thrombosis .
Tranexamic acid reduces perioperative blood transfusions following open radical cystectomy - a propensity-score matched analysis

Luisa Egen,Karoline Keller,Hanna Saskia Menold,Allison Quan,Carl-Erik Dempfle,Jochen Johannes Schoettler,Frederik Wessels,Benjamin Meister,Thomas Stefan Worst,Niklas Westhoff,Maximilian Christian Kriegmair,Patrick Honeck,Maurice Stephan Michel,Karl-Friedrich Kowalewski

DOI: https://doi.org/10.1007/s00345-024-05168-x

2024-08-08

Abstract:Purpose: Radical cystectomy is associated with bleeding and high transfusion rates, presenting challenges in patient management. This study investigated the prophylactic use of tranexamic acid during radical cystectomy. Methods: All consecutive patients treated with radical cystectomy at a tertiary care university center were included from a prospectively maintained database. After an institutional change in the cystectomy protocol patients received 1 g of intravenous bolus of tranexamic acid as prophylaxis. To prevent bias, propensity score matching was applied, accounting for differences in preoperative hemoglobin, neoadjuvant chemotherapy, tumor stage, and surgeon experience. Key outcomes included transfusion rates, complications, and occurrence of venous thromboembolism. Results: In total, 420 patients were included in the analysis, of whom 35 received tranexamic acid. After propensity score matching, 32 patients and 32 controls were matched with regard to clinicopathologic characteristics. Tranexamic acid significantly reduced the number of patients who received transfusions compared to controls (19% [95%-Confidence interval = 8.3; 37.1] vs. 47% [29.8; 64.8]; p = 0.033). Intraoperative and postoperative transfusion rates were lower with tranexamic acid, though not statistically significant (6% [1.5; 23.2] vs. 19% [8.3; 37.1], and 16% [6.3; 33.7] vs. 38% [21.9; 56.1]; p = 0.257 and p = 0.089, respectively). The occurrence of venous thromboembolism did not differ significantly between the groups (9% [2.9; 26.7] vs. 3% [0.4; 20.9]; p = 0.606). Conclusion: Prophylactic tranexamic administration, using a simplified preoperative dosing regimen of 1 g as a bolus, significantly lowered the rate of blood transfusion after cystectomy. This exploratory study indicates the potential of tranexamic acid in enhancing outcomes of open radical cystectomy.
Tranexamic acid reduces blood loss during orthotopic liver transplantation

Khaled Yassen,Mark C. Bellamy,Sami A. Sadek,Nigel R. Webster

DOI: https://doi.org/10.1111/j.1399-0012.1993.tb00722.x

1993-10-01

Clinical Transplantation

Abstract:We have studied bleeding and fibrinolysis in 20 patients undergoing orthotopic liver transplantation. Ten were randomized to receive tranexamic acid during the anhepatic (stage II) and reperfusion (stage III) phases as prophylaxis against fibrinolysis. The other 10 patients acted as controls. Overall blood loss was less (p<0.05) and abnormal clot lysis (defined as a dilute whole blood clot lysis time of less than 2 hours) was seen less frequently (p=0.0015) in the treatment group as compared with the control group. Clot formation rate as assessed by thrombclastography (TEG) was also significantly belter in the treatment group (p < 0.05). Blood product requirements were reduced in the treatment group as compared with the controls but this difference failed to reach significance in this study. Tranexamic acid has an important role to play in the prophylaxis of major hemorrhage in patients undergoing liver transplantation.

surgery,transplantation
Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single‐Blind Randomized Controlled Trial

Xin-die Zhou,Yi Zhang,Li-feng Jiang,Jun-jie Zhang,Dong Zhou,Li-dong Wu,Yong Huang,Nan-wei Xu

DOI: https://doi.org/10.1111/os.12511

2019-01-01

Orthopaedic Surgery

Abstract:Objective To investigate the efficacy and safety of tranexamic acid (TXA) in the reduction of bleeding and the need for transfusion in elderly intertrochanteric fracture patients. Methods A total of 100 patients with intertrochanteric fractures undergoing surgery were enrolled and randomly allocated to the TXA group in which patients (75.10 ± 8.27 years old) were treated with 1 g of TXA, or the control group (77.82 ± 6.42 years old) treated with a placebo. Surgery was performed by two senior orthopaedic surgeons from two institutions. The proximal femoral nail antirotation (PFNA) was conducted using the standard procedure. Three outcome measures, including blood loss, transfusion, and complications, were recorded. Blood loss and transfusion were investigated to assess TXA's effectiveness, while complications were investigated to assess TXA's safety. Statistical indicators for blood loss included total, intraoperative, postoperative, and hidden blood loss volumes, calculated by hemoglobin levels, hematocrit levels, and drainage volume. The number and amount of blood transfusions were recorded. Complications associated with surgery, including deep vein thrombosis, pulmonary embolism, wound hematoma, wound infection, cardiovascular and cerebrovascular accidents, and respiratory infections, were also recorded. Results All patients were followed up for 1 month after surgery. There were no significant differences in demographic and clinical characteristics between the two groups. The TXA group suffered significantly less total blood loss (563.37 ± 197.51 vs 819.25 ± 273.96 mL, 95% CI : −349.49 to −162.27, P < 0.01), intraoperative blood loss (140.3 ± 80.64 vs 230.5 ± 130.56 mL, 95% CI −132.74 to −47.66, P < 0.01), and hidden blood loss (410.42 ± 178.23 vs 571.19 ± 218.13 mL, 95% CI : −238.85 to −82.69, P < 0.01) than the control group. However, postoperative total blood loss was not significantly different (97.5 ± 20.93 vs 94.7 ± 35.78 mL; P = 0.63). A total of 5 patients from the TXA group and 27 from the control group received packed RBC for postoperative transfusion, but the mean number of transfusion units was not significantly different between groups. Complications including deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic cerebral infarction, hematoma, and infection were observed in both groups, but no significant differences were found. Conclusions In intertrochanteric fracture surgery performed using PFNA, intravenous administration of TXA significantly reduced the risk of intraoperative, total and hidden blood loss, in addition to the need for allogeneic transfusion, without increasing the rate of complications.
Intravenous Tranexamic Acid Decreases Blood Transfusion in Off-Pump Coronary Artery Bypass Surgery: A Meta-analysis.

Liang Sun,Haiyan An,Yi Feng

DOI: https://doi.org/10.1532/hsf.2797

2020-01-01

Abstract:BACKGROUND:Tranexamic acid (TXA) has been widely used during on-pump coronary artery bypass graft (CABG) surgery owing to its antifibrinolytic effect. However, the efficacy and safety of TXA in off-pump CABG surgery remains unconfirmed, especially intravenous (IV) administration.OBJECTIVE:The aim of this study was to evaluate the effectiveness and safety of IV administration of TXA in off-pump CABG settings.METHODS AND RESULTS:A comprehensive literature search was performed to identify randomized controlled trials (RCTs) that compared IV use of TXA with placebo in the reduction of postoperative 24-hour blood transfusion, as well as postoperative death and thrombotic events. The combined estimations were compiled with a fixed-effects model or, if heterogeneity existed, a random-effects model. Funnel plots and Egger's test were used to assess potential publication bias. Subgroup analyses were used to explore possible sources of heterogeneity. In total, 12 RCTs met the inclusion criteria. IV administration of TXA significantly reduced the risk of packed red blood cell (PRBC) transfusion [risk ratio (RR) = 0.61, 95% confidence interval (CI) 0.503 to 0.756, P < .001, I2 = 0.0%) during the 24 hours after surgery. However, there was no statistical significance in platelet (RR = 0.613, 95% CI 0.112 to 3.348, P = .572, I2 = 0.0%) or total fresh frozen plasma (FFP) (RR = 0.511, 95% CI 0.246 to 1.063, P = .073, I2 = 0.0%) transfusion. Also, no significant difference was found in major adverse events (death or thrombotic complications) (RR = 0.917, 95% CI 0.532 to 1.581, P = .756, I2 = 0.0%) between the 2 groups. Interestingly, further subgroup analysis demonstrated that IV TXA decreased the risk of prothrombin time (PT)- and international normalized ratio (INR)-guided FFP transfusion (RR = 0.462, 95% CI 0.296 to 0.721, P = .001, I2 = 0.0%).CONCLUSION:IV TXA was effective in reducing allogeneic blood component transfusion (PRBCs and PT- or INR-guided FFP transfusion), without increasing the incidence of postoperative death or thrombotic complications in off-pump CAB surgery.
Tranexamic Acid Administered During Off-Pump Coronary Artery Bypass Graft Surgeries Achieves Good Safety Effects and Hemostasis

Enshi Wang,Xin Yuan,Yang Wang,Weinan Chen,Xingtong Zhou,Shengshou Hu,Su Yuan

DOI: https://doi.org/10.3389/fcvm.2022.775760

IF: 3.6

2022-02-04

Frontiers in Cardiovascular Medicine

Abstract:Background Tranexamic acid (TXA) administered during off-pump coronary artery bypass (OPCAB) surgeries has achieved good blood control in small cohorts. We aimed to investigate the safety issues and hemostasis associated with TXA administration during OPCAB in a large retrospective cohort study. Methods This study included 19,687 patients with OPCAB from 2009 to 2019. A total of 1,307 patients were excluded because they were younger than 18 years or certain values were missing. Among the remaining 18,380 patients, 10,969 were in the TXA group and 7,411 patients were in the no-TXA group. There were 4,889 patients whose TXA dose was ≥50 mg/kg, and the remaining 6,080 patients had a TXA dose of <50 mg/kg. Propensity score matching (PSM) was performed between the TXA and no-TXA groups and between the high-dose and low-dose groups, and statistical analysis was performed. Results Tranexamic acid administration did not increase the risk of hospital death or thromboembolic events. Patients who administered TXA had less blood loss at 24 h (478.32 ± 276.41 vs. 641.28 ± 295.09, p < 0.001) and 48 h (730.59 ± 358.55 vs. 915.24 ± 390.13, p < 0.001) and total blood loss (989.00 ± 680.43 vs. 1,220.01 ± 720.68, p < 0.001) after OPCAB than the patients with non-TXA. Therefore, the risk of total blood exposure [odds ratio (OR) = 0.50, 95% CI 0.47–0.54, p < 0.001] or blood component exposure ( p < 0.001) was decreased significantly in the patients who administered TXA. The TXA dosage did not impact the patient survival, thromboembolic events, or blood management. Conclusions The application of TXA was safe and provided blood control in patients with OPCAB, and the dosage did not affect these parameters.

cardiac & cardiovascular systems
Use of Tranexamic Acid to Reduce PostOperative Bleeding in Orthopaedic Oncology

Lorenzo Andreani,Andrea Del Chiaro,Edoardo Ipponi,Federico Di Sacco,Martina Caterino,Rodolfo Capanna

DOI: https://doi.org/10.15388/amed.2022.29.2.17

2022-12-12

Acta medica Lituanica

Abstract:Background: Orthopaedic oncology often causes major blood losses that may put at risk patients’ hemodynamic balance and their overall clinical stability. To this date, transfusion therapy still represents the pivotal treatment to counterbalance the reduction in hemoglobin levels which occur after surgery. Although effective, transfusions are expensive and inevitably associated with a number of complications and therefore other solutions, such as procoagulative drugs, could play an important role to prevent massive blood losses.Material and methods: We reviewed the clinical intercourse of 37 patients who underwent major bone resection due to malignant tumors of the lower limb. Cases were divided in two different groups: group G1 consisting of 12 patients treated intraoperatively with tranexamic acid and group G2 which was made of 25 controls.Results: On average, patients treated with tranexamic acid (G1) required transfusion of 3.9 concentrated blood cells units during surgery and 0.9 units during the postoperative course. Other patients (G2), for their part, required on average 3.1 units intraoperatively and 2.1 units postoperatively. No significant difference was found in intraoperative transfusion rate (p=0.402). Instead, postoperative transfusions were significantly less frequent for patients treated with tranexamic acid (p=0.023). None of the 12 patients treated with tranexamic acid had evidence of Deep Vein Thrombosis.Conclusion: Our outcomes indicate that the use of TXA was effective in reducing blood losses also for major surgical interventions in orthopedic oncology.
Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial

Paul J Karanicolas,Yulia Lin,Stuart A McCluskey,Jordan Tarshis,Kevin E Thorpe,Alice Wei,Elijah Dixon,Geoff Porter,Prosanto Chaudhury,Sulaiman Nanji,Leyo Ruo,Melanie E Tsang,Anton Skaro,Gareth Eeson,Sean Cleary,Carol-Anne Moulton,Chad G Ball,Julie Hallet,Natalie Coburn,Pablo E Serrano,Shiva Jayaraman,Calvin Law,Ved Tandan,Gonzalo Sapisochin,David Nagorney,Douglas Quan,Rory Smoot,Steven Gallinger,Peter Metrakos,Trevor W Reichman,Diederick Jalink,Sean Bennett,Francis Sutherland,Edward Solano,Michele Molinari,Ephraim S Tang,Susanne G Warner,Oliver F Bathe,Jeffrey Barkun,Michael L Kendrick,Mark Truty,Rachel Roke,Grace Xu,Myriam Lafreniere-Roula,Gordon Guyatt,HPB CONCEPT Team

DOI: https://doi.org/10.1001/jama.2024.11783

IF: 11.816

2024-08-19

JAMA

Abstract:Importance: Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect in patients undergoing liver resection for a cancer-related indication remains unclear. Objective: To determine whether tranexamic acid reduces red blood cell transfusion within 7 days of liver resection. Design, setting, and participants: Multicenter randomized clinical trial of tranexamic acid vs placebo conducted from December 1, 2014, to November 8, 2022, at 10 hepatopancreaticobiliary sites in Canada and 1 site in the United States, with 90-day follow-up. Participants, clinicians, and data collectors were blinded to allocation. A volunteer sample of 1384 patients undergoing liver resection for a cancer-related indication met eligibility criteria and consented to randomization. Interventions: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n = 619) or matching placebo (n = 626) beginning at induction of anesthesia. Main outcomes and measures: The primary outcome was receipt of red blood cell transfusion within 7 days of surgery. Results: The primary analysis included 1245 participants (mean age, 63.2 years; 39.8% female; 56.1% with a diagnosis of colorectal liver metastases). Perioperative characteristics were similar between groups. Red blood cell transfusion occurred in 16.3% of participants (n = 101) in the tranexamic acid group and 14.5% (n = 91) in the placebo group (odds ratio, 1.15 [95% CI, 0.84-1.56]; P = .38; absolute difference, 2% [95% CI, -2% to 6%]). Measured intraoperative blood loss (tranexamic acid, 817.3 mL; placebo, 836.7 mL; P = .75) and total estimated blood loss over 7 days (tranexamic acid, 1504.0 mL; placebo, 1551.2 mL; P = .38) were similar between groups. Participants receiving tranexamic acid experienced significantly more complications compared with placebo (odds ratio, 1.28 [95% CI, 1.02-1.60]; P = .03), with no significant difference in venous thromboembolism (odds ratio, 1.68 [95% CI, 0.95-3.07]; P = .08). Conclusions and relevance: Among patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications. Trial registration: ClinicalTrials.gov Identifier: NCT02261415.
Tranexamic Acid Reduces Blood Loss, Transfusion Requirements, and Coagulation Factor Use in Primary Orthotopic Liver Transplantation

John F. Boylan,John R. Klinck,Alan N. Sandler,Ramiro Arellano,Paul D. Greig,Hilary Nierenberg,Sandra L. Roger,Michael F. X. Glynn

DOI: https://doi.org/10.1097/00000542-199611000-00012

IF: 8.986

1996-11-01

Anesthesiology

Abstract:Background Patients with end-stage liver disease frequently incur large-volume blood loss during liver transplantation associated with mechanical factors, preexisting coagulopathy, and intraoperative fibrinolysis. Methods Between April 1992 and May 1994, the authors of this double-blind, randomized, placebo-controlled study examined the effect of high-dose tranexamic acid (maximum of 20 g) on blood loss and blood product requirements in patients undergoing primary isolated orthotopic liver transplantation. Primary outcome measures were volume of blood loss (intraoperative blood loss and postoperative drainage) and erythrocyte, plasma, platelet, and cryoprecipitate use during surgery and the first 24 h of intensive care unit stay. Results Patients receiving tranexamic acid (n = 25) had less intraoperative blood loss (median, 4.3 l; interquartile range, 2.5 to 7.9; P = 0.006) compared with the placebo group (n = 20; median, 8 l; interquartile range, 5 to 15.8), and reduced intraoperative plasma, platelet, and cryoprecipitate requirements. Median perioperative erythrocyte use was 9 units (interquantile range, 4 to 14 units) in patients receiving tranexamic acid and 13 units (interquantile range, 7.5 to 31 units) in controls (P = 0.03). Total perioperative donor exposure was 20.5 units (interquantile range, 16 to 41 units) in patients receiving tranexamic acid and 43.5 units (interquantile range, 29.5 to 79 units) in controls (P = 0.003). Results for postoperative wound drainage were similar. Hospital stay and need for retransplantation were comparable in both groups. No patient in either group showed clinical evidence of hepatic artery or portal venous thrombosis within 1 month of transplantation. Conclusions High-dose tranexamic acid significantly reduces intraoperative blood loss and perioperative donor exposure in patients with end-stage parenchymal liver disease who are undergoing orthotopic liver transplantation, with marked reductions in platelet and cryoprecipitate requirements.

anesthesiology
Blood loss and limb circumference changes in patients undergoing unilateral total knee arthroplasty after intra-articular injection of tranexamic acid:a randomized controlled trial

Jin-hui Ma,Wei Sun,Fu-qiang Gao,Yun-ting Wang,Zi-rong Li

DOI: https://doi.org/10.3969/j.issn.2095-4344.2014.35.001

2014-01-01

Abstract:BACKGROUND:Tranexamic acid has been more and more used in reducing bleeding after joint replacement, but its usage method and dosage remain controversial, and become a hot focus in recent years. OBJECTIVE:To investigate the efficacy of intra-articular injection of tranexamic acid on postoperative blood loss and limb circumference changes in patients who received unilateral total knee arthroplasty. METHODS:From March to October 2013, clinical data of 90 patients undergoing primary unilateral total knee arthroplasty were randomized to the tranexamic acid group and the control group, including 19 males and 71 females. The 30 patients in the tranexamic acid group received 50 mL of 3%tranexamic acid dilute solution inside knee joint after capsule closure, and 60 patients in the control group received the same volume of physiological saline. No significant difference in age, height, body mass index, anticoagulation, the type of prosthesis, tourniquet time and preoperative diagnosis was detected between the two groups (P>0.05). The amounts of intraoperative and postoperative blood loss and blood transfusion, postoperative drainage volume, the preoperative and postoperative limb circumference 10 cm above the operated knee were recorded. Routine blood test was reviewed after the surgery. RESULTS AND CONCLUSION:There were no significant differences in total blood loss, postoperative drainage volume and limb circumference changes between tranexamic acid and control groups (P>0.05). The amount of postoperative hidden blood loss was significantly less in the tranexamic acid group than in the control group (t=-2.683, P<0.05). These data suggested that the intra-articular injection of tranexamic acid intraoperatively in patients receiving total knee arthroplasty could significantly reduce the amounts of postoperative hidden blood loss, and did not affect the postoperative limb circumference changes.
The Efficacy and Safety of Topical Tranexamic Acid for Spinal Surgery

Tai Guo,Wenxia Xuan,Haoyu Feng,Junjie Wang,Xun Ma

DOI: https://doi.org/10.2174/1381612827666210713160016

IF: 3.31

2021-11-19

Current Pharmaceutical Design

Abstract:Background: Spinal surgeries are often accompanied by significant blood loss both intraoperatively and postoperatively. Excessive blood loss caused by surgery may lead to several unsatisfactory medical consequences. Tranexamic acid (TXA) is a kind of antifibrinolytic agent that has been widely used in spinal surgery. Currently, it is widely accepted that intravenous TXA (ivTXA) can clearly reduce blood loss in spinal fusion surgeries. Compared with ivTXA, topical TXA (tTXA) seems to be much easier to administer, and this advantage provides a maximum concentration of TXA at the haemorrhagic site with little to no TXA entering the circulation. Objective: To evaluate the effect of tTXA on blood loss during and after spinal surgery via a comprehensive metaanalysis of the published data in randomized controlled trials (RCTs) and other comparative cohort studies. Methods: A comprehensive search of PubMed, EMBASE, the Web of Science and the Cochrane Central Register of Controlled Trials was performed for RCTs and other comparative cohort studies on the effect of tTXA on blood loss during and after spinal surgery. The outcomes were total blood loss, hidden blood loss, intraoperative blood loss, total postoperative drainage volume, drainage tube duration postoperatively, drainage volume and drainage of blood content at postoperative day (POD) 1 and POD2, length of hospital stay, number of patients who received a blood transfusion, serum HB level at POD1, operative timespan, side effects and complications. The final search was performed in October, 2020. We followed the PRISMA guideline, and the registration number is INPLASY202160028. Results: In total, 6 studies with 481 patients were included. tTXA treatment, compared with the control conditions, can significantly reduce the total blood loss, hidden blood loss, total postoperative drainage volume, and number of patients receiving blood transfusions; reduce the drainage volume and drainage of blood content at POD1; shorten the drainage tube duration postoperatively and length of hospital stay; and enhance the serum HB level at POD1 for spinal surgery. tTXA treatment did not significantly influence the intraoperative blood loss, drainage volume or drainage of blood content at POD2 or the operative duration. Conclusion: Compared with control conditions, tTXA has high efficacy in reducing blood loss and drainage volume, enables quick rehabilitation, and has a relatively high level of safety in spinal surgery.

pharmacology & pharmacy
Blood conservation outcomes and safety of tranexamic acid in coronary artery bypass graft surgery

Enshi Wang,Xin Yuan,Yang Wang,Weinan Chen,Xingtong Zhou,Shengshou Hu,Su Yuan

DOI: https://doi.org/10.1016/j.ijcard.2021.12.017

IF: 4.039

2022-02-01

International Journal of Cardiology

Abstract:BACKGROUND: The safety and blood management effects of Tranexamic acid (TXA) and its dose effects in coronary artery bypass graft (CABG) were still ambiguous. This study aimed to analyze these TXA effects.METHODS: Overall, 42,010 patients undergoing CABG were enrolled in this retrospective cohort study. Patients were assigned to the TXA group (n = 29,536) and the no-TXA group (n = 12,474). Furthermore, the TXA group was divided into the high-dose (≥50 mg/kg) (16,488) and the low-dose (<50 mg/kg) (13,048) subgroup. Propensity score matching was performed in both groups respectively. The primary endpoint after CABG was composed of hospital death, perioperative myocardial infarction (PMI), stroke, acute kidney injury (AKI), and pulmonary embolism. The secondary endpoint included blood loss and blood transfusion after surgery.RESULTS: TXA led to a 1.40-fold risk of PMI (p < 0.001). Patients in the TXA group had fewer re-operations for bleeding or tamponade [Odd ratio (OR) = 0.82, p = 0.044], less blood loss after surgery (p < 0.001), and a lower risk for blood transfusion exposure (OR = 0.45, p < 0.001) than those in the no-TXA group. The high-dose TXA reduced blood loss after cardiac surgery compared to the low-dose TXA (p < 0.001) with no associations with blood exposure or adverse events.CONCLUSIONS: The use of TXA during CABG increased the risk of PMI despite better blood control after surgery. The high dose of TXA acquired better bleeding management. Meanwhile, it did not increase the risk of primary endpoint.

cardiac & cardiovascular systems
Clinical Use of Tranexamic Acid in High Tibial Osteotomy: A Systematic Review and Meta-analysis

Zheshu Xu,Lixun Li,Peng Xie,Juyuan Gu,Kai Kang,Xiaozuo Zheng

DOI: https://doi.org/10.1177/23259671241231761

IF: 2.6

2024-03-08

Orthopaedic Journal of Sports Medicine

Abstract:Orthopaedic Journal of Sports Medicine, Volume 12, Issue 3, March 2024. Background:High tibial osteotomy (HTO) can cause postoperative hemorrhage. The use of tranexamic acid to reduce the hemorrhage is still controversial.Purpose:To investigate the efficacy and safety of tranexamic acid in HTO.Study Design:Systematic review; Level of evidence, 4.Methods:Using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, the authors conducted a comprehensive search of the Embase, Cochrane Library, PubMed, Web of Science, MEDLINE, and Foreign Medical Literature Retrieval Service databases between their inception and January 1, 2023. All clinical studies comparing the use of tranexamic acid versus no tranexamic acid during HTO were collected. The primary outcome measures were hemoglobin decrease, drainage volume, and blood loss, and the secondary outcome measures were wound complications, blood transfusion, and postoperative thrombosis. All indicators were analyzed using meta-analysis software. Results were reported as mean differences or risk ratios with 95% confidence intervals.Results:Of 152 initial results, 9 studies involving 908 patients were included. The tranexamic acid group had lower indicators for total blood loss, hemoglobin decrease, and total drainage volume (P < .00001 for all). There were no differences between patients with versus without tranexamic acid in wound complications, including hematoma (P = .21) or infection (P = .18), nor were there any group differences in the prevalence of blood transfusion (P = .21) or postoperative thrombosis (P = .36).Conclusion:Tranexamic acid was able to effectively reduce postoperative hemorrhage in patients undergoing HTO without affecting the rates of wound complications, blood transfusion, or postoperative thrombosis.

orthopedics,sport sciences

Tranexamic Acid Reduces Blood Loss after Off-Pump Coronary Surgery

Tranexamic acid reduces blood loss after off-pump coronary surgery: a prospective, randomized, double-blind, placebo-controlled study.

Tranexamic acid reduces postoperative bleeding in coronary artery bypass graft

Effect of Preoperative Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss Control in Patients Undergoing Cesarean Delivery: a Systematic Review and Meta-Analysis

Tranexamic acid for upper gastrointestinal bleeding

Effectiveness And Safety Of Tranexamic Acid In Reducing Blood Loss In Total Knee Arthroplasty: A Meta-Analysis

Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials

Systemic Tranexamic Acid for Reduced Postoperative Blood Loss and Less Bleeding Complications in Fleur-de-lis Abdominoplasty and Apronectomy

Effects of tranexamic acid in total knee arthroplasty by intra-articular injection on reducing blood loss：a prospective randomized controlled study

Tranexamic acid reduces perioperative blood transfusions following open radical cystectomy - a propensity-score matched analysis

Tranexamic acid reduces blood loss during orthotopic liver transplantation

Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single‐Blind Randomized Controlled Trial

Intravenous Tranexamic Acid Decreases Blood Transfusion in Off-Pump Coronary Artery Bypass Surgery: A Meta-analysis.

Tranexamic Acid Administered During Off-Pump Coronary Artery Bypass Graft Surgeries Achieves Good Safety Effects and Hemostasis

Use of Tranexamic Acid to Reduce PostOperative Bleeding in Orthopaedic Oncology

Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial

Tranexamic Acid Reduces Blood Loss, Transfusion Requirements, and Coagulation Factor Use in Primary Orthotopic Liver Transplantation

Blood loss and limb circumference changes in patients undergoing unilateral total knee arthroplasty after intra-articular injection of tranexamic acid:a randomized controlled trial

The Efficacy and Safety of Topical Tranexamic Acid for Spinal Surgery

Blood conservation outcomes and safety of tranexamic acid in coronary artery bypass graft surgery

Clinical Use of Tranexamic Acid in High Tibial Osteotomy: A Systematic Review and Meta-analysis